Faye C. Austin, Ph.D., Director for Research
Faye C. Austin, Ph.D., Director for Research
With a research background in cancer immunology, Austin came to Dana-Farber in November 1998 after directing the National Cancer Institute's (NCI) Division of Cancer Biology for three years. Widely considered an expert in formulating policy for federal support and funding of cancer research, she is responsible for developing and leading the activities that support scientific investigation at the Institute. These include grant and contract management, operation of research laboratories and the research library, the patent counsel's office, technology transfer, and clinical trials support.
A member of the NCI staff since 1976, Austin held a wide variety of research and policymaking positions in which she was responsible for initiatives ranging from breast cancer research to cancer immunology. She earned a B.S. in chemistry and an M.S. in biochemistry from Penn State University and her Ph.D. in microbiology from George Washington University.
"This is a time of unprecedented scientific discovery that can and will lead to new approaches in cancer prevention, diagnosis and treatment, " said Austin at the time of her arrival. "I'm very pleased to be joining Dana-Farber at this time of growth and development of new collaborative activities in clinical care and research."
Ronald DePinho, M.D., Department of Adult Oncology
His research into the workings of cell biological clocks and tumor suppression mechanisms has attracted national attention and won numerous awards and honors. Coming to Dana-Farber in August 1998 from Albert Einstein College of Medicine in New York, DePinho has focused his research on the genetic changes that occur as normal cells are transformed to cancer cells.
Ronald DePinho, M.D., Department of Adult Oncology
Now serving as co-principal investigator with Stanley Korsmeyer, M.D., of the Arthur and Rochelle Belfer Cancer Genomics Center (see pages 2 and 3), DePinho has done extensive work on the genes for telomeres, strands of DNA that serve as gatekeepers of cell growth and survival.
A graduate of Fordham College in New York, DePinho received his M.D. from Albert Einstein College of Medicine and completed postgraduate training at Columbia-Presbyterian and Albert Einstein. His interest in Dana-Farber stemmed from the Institute's reputation for blending cutting-edge cancer research with highly respected clinical care.
"For many years, Dana-Farber has played a leading role in studying the basic molecular mechanisms that lead to cancer, and in developing new therapies and diagnostic tests," he said. "I'm proud to be affiliated with an organization dedicated to improving the human condition."
Dirk Iglehart, M.D., Director of Research,Women's Cancers Program
Dirk Iglehart, M.D., Director of Research,Women's Cancers Program
Arriving in July 1999 to see patients at the Gillette Center for Women's Cancers and direct the Institute's breast cancer research efforts as the Charles A. Dana Senior Investigator in Cancer Genetics, Iglehart is known for his ability to bring teams of investigators together to solve complex and important problems.
He comes to Dana-Farber from Duke University Medical Center, where he was a surgeon with a reputation for doing groundbreaking research in breast cancer detection and treatment. Dividing his time evenly at the Gillette Center between clinical and research duties, Iglehart hopes to focus primarily on breast cancer risk assessment and prevention. He also serves as the Richard Wilson Professor of Surgery at Brigham and Women's Hospital (BWH) and Harvard Medical School, and as chief of the Division of Surgical Oncology at BWH.
His appointment is a homecoming of sorts for Iglehart, who graduated from Harvard Medical School in 1974 and worked in a Dana-Farber lab during his final year. Heading that lab was David Livingston, M.D., who describes Iglehart as "one of the most gifted leaders of complex translational research efforts, who helped transform Duke from a large institution into a major national power in breast cancer research."
- Next: Bruce Johnson, M.D., Director, Lowe Center for Thoracic Oncology
- Page: 1 | 2 | 3
